BR112019009511A2 - polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento. - Google Patents

polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.

Info

Publication number
BR112019009511A2
BR112019009511A2 BR112019009511A BR112019009511A BR112019009511A2 BR 112019009511 A2 BR112019009511 A2 BR 112019009511A2 BR 112019009511 A BR112019009511 A BR 112019009511A BR 112019009511 A BR112019009511 A BR 112019009511A BR 112019009511 A2 BR112019009511 A2 BR 112019009511A2
Authority
BR
Brazil
Prior art keywords
formulation
polypeptide
pharmaceutically acceptable
treatment
medicament
Prior art date
Application number
BR112019009511A
Other languages
English (en)
Inventor
Pollett Jonathan
Thai Ngoc
Original Assignee
Imagine Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma filed Critical Imagine Pharma
Publication of BR112019009511A2 publication Critical patent/BR112019009511A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção provê uma composição compreendendo uma quantidade terapeuticamente eficaz de um polipeptídeo, peptídeo ou análogo, correspondente a uma ou mais das seq id nos 1, 2, 3 ou 4, e/ou mais de um veículo farmaceuticamente aceitável, diluente farmaceuticamente aceitável e/ou excipiente farmaceuticamente aceitável. o polipeptídeo terapêutico da presente invenção pode ser formulado para administração a um indivíduo com necessidade de tratamento como uma formulação oral, uma formulação parenteral, uma formulação tópica, uma formulação aquosa, uma formulação sólida, uma formulação liofilizada ou uma formulação transdérmica. além disso, é descrito um método para tratar pelo menos um dentre diabetes e/ou hiperglicemia e/ou hipercolesterolemia e/ou hipertensão e/ou síndrome metabólica em um indivíduo, compreendendo: administrar ao indivíduo um polipeptídeo da invenção ou uma formulação da invenção.
BR112019009511A 2016-11-13 2017-11-13 polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento. BR112019009511A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421332P 2016-11-13 2016-11-13
PCT/US2017/061343 WO2018089909A1 (en) 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Publications (1)

Publication Number Publication Date
BR112019009511A2 true BR112019009511A2 (pt) 2019-07-30

Family

ID=62107069

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019009511A BR112019009511A2 (pt) 2016-11-13 2017-11-13 polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.

Country Status (10)

Country Link
US (2) US10548941B2 (pt)
EP (1) EP3538124A4 (pt)
JP (2) JP2020502056A (pt)
KR (1) KR102497242B1 (pt)
CN (1) CN110087666B (pt)
AU (2) AU2017357052B2 (pt)
BR (1) BR112019009511A2 (pt)
CA (1) CA3041362A1 (pt)
MX (1) MX2019005466A (pt)
WO (1) WO2018089909A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041362A1 (en) * 2016-11-13 2018-05-17 Imagine Pharma, Llc Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
KR20210013543A (ko) * 2018-01-09 2021-02-04 이매진 파마 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도
AU2019295576B2 (en) * 2018-06-25 2024-04-04 Imagine Pharma, Llc Compositions and methods for propagating insulin-producing islet cells and therapeutic uses thereof
CN110974943A (zh) * 2019-12-09 2020-04-10 广东药科大学 一种口服胰岛素药物制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3917258B2 (ja) * 1997-04-09 2007-05-23 花王株式会社 新規アルカリペクチン酸リアーゼ及びその製造法
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AUPR311601A0 (en) * 2001-02-15 2001-03-08 Adp Pharmaceutical Pty Limited Matrix gene expression in chondrogenesis
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
WO2003068908A2 (en) * 2001-07-10 2003-08-21 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
EP2275127B1 (en) * 2002-04-02 2012-09-19 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
WO2005000335A2 (en) * 2003-06-02 2005-01-06 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
JP2005245202A (ja) * 2004-03-01 2005-09-15 Japan Science & Technology Agency ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能
WO2008127813A1 (en) * 2007-03-09 2008-10-23 Hiberna Corporation Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use
WO2010129023A2 (en) * 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
US20140080824A1 (en) * 2010-10-21 2014-03-20 New York University Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
US20130236917A1 (en) * 2010-11-12 2013-09-12 The Johns Hopkins University Albumin-bound protein/peptide complex as a biomarker for disease
PL3447061T3 (pl) 2011-03-01 2022-01-31 NuCana plc Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu
WO2015048334A2 (en) * 2013-09-25 2015-04-02 Pronutria, Inc. Edible species nutritive polypeptides and methods of production and use thereof
PE20171058A1 (es) * 2014-10-31 2017-07-21 Ngm Biopharmaceuticals Inc Composiciones y metodos de uso para tratar trastornos metabolicos
CN108367053A (zh) * 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
CA3041362A1 (en) * 2016-11-13 2018-05-17 Imagine Pharma, Llc Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
KR20210013543A (ko) * 2018-01-09 2021-02-04 이매진 파마 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도

Also Published As

Publication number Publication date
CA3041362A1 (en) 2018-05-17
US10751384B2 (en) 2020-08-25
AU2017357052B2 (en) 2022-03-24
EP3538124A4 (en) 2020-07-22
WO2018089909A1 (en) 2018-05-17
KR20190084070A (ko) 2019-07-15
US20180133280A1 (en) 2018-05-17
US20200222499A1 (en) 2020-07-16
EP3538124A1 (en) 2019-09-18
AU2022203741A1 (en) 2022-06-23
MX2019005466A (es) 2019-10-02
US10548941B2 (en) 2020-02-04
JP2020502056A (ja) 2020-01-23
KR102497242B1 (ko) 2023-02-09
CN110087666B (zh) 2024-04-30
CN110087666A (zh) 2019-08-02
AU2022203741B2 (en) 2024-02-15
JP2023071670A (ja) 2023-05-23
AU2017357052A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
RU2010101892A (ru) Гиалуронидаза и способ ее применения
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
MX2010008802A (es) Formulacion liquida de la fsh.
JP2015517488A5 (pt)
RU2739037C3 (ru) Композиция для контролируемой стимуляции яичников
BR0313388A (pt) Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
RU2012131251A (ru) Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
JP2017533972A5 (pt)
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
BR112014030777A2 (pt) método e composição para aliviar sintomas de tumor
BR112019002655A2 (pt) composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora
MY193963A (en) Composition for treating joint diseases and kit containing same
WO2014129818A1 (ko) 당뇨병성 창상의 예방 또는 치료용 약학 조성물
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
BR112017022390A2 (pt) composição farmacêutica
BR112018016817A2 (pt) composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]